Yale-Brown Obsessive Compulsive Scale

The Yale-Brown Obsessive-Compulsive Scale (Y-BOSC) is considered the gold-standard to assess OCD severity. The scale consists of ten items and measures the severity and type of symptoms in people with OCD over the previous seven days. The scale is used at initial diagnosis as well as during follow up sessions after treatment. The scores range from 0 to 4, with higher scores indicating greater symptoms of OCD severity.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account

Find out more about The Yale Brown Obsessive-Compulsive Scale

Alternative name

Active? Yes

First used: 13 October 2021

Related Topic

Obsessive-Compulsive Disorder
OCD affects an estimated 1-2% of the population and is ranked as one of the 10 most disabling illnesses in terms of lost income and decreased quality of life in tandem with medications like SSRIs is the most common treatment. Phase I studies using psilocybin to treat OCD are underway.

Related Trials

Effects of Repeated Psilocybin Dosing in OCD
This study aims to investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology in a randomized, waitlist-controlled design with blinded independent ratings, and assess psychological mechanisms that may mediate psilocybin's therapeutic effects on OCD.

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study
This study aims to investigate the effects of oral psilocybin on OCD symptomatology and provide the first evidence of the neural mechanism that may mediate psilocybin's purported therapeutic effects on OCD.

Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD
The purpose of the current study is to explore new alternative options for the treatment of OCD that can widely and continuously benefit patients. Specifically, the aim of this study is to investigate the feasibility, safety and efficacy of psilocybin-assisted psychotherapy for treatment of severe OCD. 

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study, 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Follow-up visits to monitor safety and clinical outcome will be conducted over a 3 month period.

Inline Feedbacks
View all comments